{"id":21455,"date":"2021-12-08T13:02:33","date_gmt":"2021-12-08T08:02:33","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=83718"},"modified":"2021-12-08T13:02:33","modified_gmt":"2021-12-08T08:02:33","slug":"mrm-health-announces-first-patient-dosed-with-next-generation-live-microbiome-consortia-therapeutic-mh002-in-phase-1b-2a-study-in-patients-with-ulcerative-colitis","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/mrm-health-announces-first-patient-dosed-with-next-generation-live-microbiome-consortia-therapeutic-mh002-in-phase-1b-2a-study-in-patients-with-ulcerative-colitis\/","title":{"rendered":"MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1b\/2a Study in Patients with Ulcerative Colitis"},"content":{"rendered":"
\n
GHENT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) — MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that the first patient received MH002 in a phase 1b\/2a multi-center clinical trial in mild-to-moderate Ulcerative Colitis. MH002 is MRM Health\u2019s first clinical product candidate resulting from its proprietary and unique CORAL\u2122 platform technology.<\/strong><\/p>\n
\u201cWe are very excited about this next step in the development of MH002 in Ulcerative Colitis,\u201d said Sam Possemiers, Ph.D., Chief Executive Officer of MRM Health. \u201cTreatment of the first patient in this study is a major achievement for our team, a milestone for the company, and an important step towards improving the lives of patients with Ulcerative Colitis (UC). We thank our Belgian and international investigators for their commitment in successfully advancing our first clinical program resulting from the CORAL\u2122 platform.\u201d<\/p>\n
MRM Health\u2019s MH002-UC-201 study is a multi-center, double-blind, randomized, placebo-controlled trial in multiple clinical sites in Belgium, Poland and Czech Republic and will enrol 45 mild-to-moderate UC patients. The trial will evaluate safety, mechanistic effects, and initial efficacy of MH002 on disease activity. More information about the trial is available at clinicaltrialsregister.eu, with identifier 2020-004355-33<\/a>.<\/p>\n